What is the price target for BEAT stock?

The 1-year base price target for BEAT (Heartbeam, Inc. Common Stock) is $0.35, implying -46.5% growth from the current price of $0.65. The 3-year base target is $0.45.

What are the bull and bear cases for BEAT?

Bull case (1Y: $1.50): Pilot data is positive enough to secure partnership/distribution and non-dilutive funding, extended-wear patch advances, and arrhythmia product gains modest concierge traction. Losses narrow, dilution slows, and market re-rates micro-cap medtech on de-risking toward FDA filing. Bear case (1Y: $0.35): Post-60% spike profit-taking and follow-on offering crush momentum. Early commercial sales disappoint as shareholder letter foreshadowed, heart-attack data is incremental not breakthrough, and FDA path extends. Continued $3M+ quarterly burn forces further dilution below $0.50, returning stock toward 52-week lows.

What is the market cap and P/E ratio of BEAT?

Heartbeam, Inc. Common Stock (BEAT) has a market cap of $36.86M and a P/E ratio of N/A (unprofitable). Revenue: N/A (~$0M pre-commercial). EPS: N/A (negative).

Equity Research · Tuesday, October 6, 2026

BEATSellUnderweight

BEAT Stock Analysis for October 2026

Q: Is BEAT stock a buy or sell?

Based on our AI-driven analysis as of 2026-10-06, BEAT (Heartbeam, Inc. Common Stock) is rated "Sell". HeartBeam (BEAT) is a 16-employee, pre-commercial medtech with real IP (26 patents, 2 FDA clearances for arrhythmia and 12-lead synthesis) and a genuinely interesting cable-free 3D ECG platform, now boosted by FDA Breakthrough Device Designation for at-home heart-attack assessment and a Mount Sinai

Q: What are the key risks for BEAT stock?

No meaningful revenue with ongoing burn and dilution: Q2 $3.3M operating outflow and $5M net loss with back-to-back $11.5M and $10M equity raises. Cash runway likely <4 quarters. Future raises at <$1 will be highly dilutive and create persistent selling pressure.. Heart-attack claim unproven and distant: Core bull thesis depends on pilot data (TCT 2026) translating to FDA clearance, reimbursement, and clinical adoption. Sensitivity/specificity for MI from ambulatory 3-lead synthesis is technically hard; failure or delay strands valuation.. Go-to-market failure and scale disadvantage: Management admits direct scaling is not working with only 16 staff. Without a strategic distributor or acquirer, concierge rollout cannot drive material revenue. Competing against entrenched ECG/Holter players with salesforces, payer contracts, and hospital IT integration.

Heartbeam, Inc. Common Stock

Price at Analysis

$0.65

1Y Target$0.35-46.5%

3Y Target$0.45-31.2%

1Y Price Target

$0.35

-46.5%

vs current price

Technical Setup

RSI 76 / bearish MACD

Support context: $0.35. Resistance context: $4.00.

Valuation Snapshot

P/E N/A (unprofitable) / P/S N/A (pre-revenue)

Market cap $36.86M; revenue N/A (~$0M pre-commercial).

Risk Watch

No meaningful revenue with ongoing burn and dilution

Q2 $3.3M operating outflow and $5M net loss with back-to-back $11.5M and $10M equity raises. Cash runway likely <4 quarters. Future raises at <$1 will be highly dilutive and create persistent selling pressure.

01 · Summary

Executive Summary

HeartBeam (BEAT) is a 16-employee, pre-commercial medtech with real IP (26 patents, 2 FDA clearances for arrhythmia and 12-lead synthesis) and a genuinely interesting cable-free 3D ECG platform, now boosted by FDA Breakthrough Device Designation for at-home heart-attack assessment and a Mount Sinai AI collaboration. That news drove a ~60% one-day spike on 404M shares (~7x shares outstanding) to $0.65, but the stock closed 31% off its $0.95 high and below VWAP ($0.74) with RSI at 75.7 — classic speculative exhaustion. Weighing all evidence, the spike prices in hope, not fundamentals. Q2 2026 showed a $5.0M net loss ($4.1M ex-transition), $3.3M quarterly operating cash burn, and reliance on dilutive raises ($11.5M + $10M offerings, the latter led by its own customer). The Sept 21, 2026 shareholder letter admits the key lesson: scaling commercialization alone is not working. The heart-attack claim — the real value driver — is still in pilot studies (ALIGN-ACS enrolled, results at TCT 2026; HEADSTART-ACS >50% enrolled) with no FDA clearance, no reimbursement, and no proven revenue. At $36.9M market cap the option value looks cheap, but cheap can get cheaper via dilution and fade after promotion.

02 · Scenario Modeling

Price Targets

1Y Base Target

$0.35-46.5%

3Y Base Target

$0.45-31.2%

1-Year scenario price targets · Dashed line = current price

02 · Scenario Modeling

Scenario Analysis

Scenario	1Y Target	1Y Growth	3Y Target	3Y Growth
↑↑Hyper Bull	$3.50	+438.5%	$7.00	+976.9%
↑Bull	$1.50	+130.8%	$3.00	+361.5%
→Neutral	$0.65	+0.0%	$0.90	+38.5%
↓Bear	$0.35	-46.2%	$0.45	-30.8%
↓↓Hyper Bear	$0.10	-84.6%	$0.05	-92.3%

↑↑Hyper Bull

1Y$4

3Y$7

1Y %+438.5%

3Y %+976.9%

↑Bull

1Y$2

3Y$3

1Y %+130.8%

3Y %+361.5%

→Neutral

1Y$1

3Y$1

1Y %+0.0%

3Y %+38.5%

↓Bear

1Y$0

3Y$0

1Y %-46.2%

3Y %-30.8%

↓↓Hyper Bear

1Y$0

3Y$0

1Y %-84.6%

3Y %-92.3%

Hyper Bull — ALIGN-ACS data at TCT 2026 is stellar, FDA clears heart-attack indication in 2027 via Breakthrough path, Mount Sinai AI proves superior, and a strategic (Philips/GE/Abbott) acquires BEAT for cable-free 12-lead + patch platform. Concierge rollout inflects to tens of millions revenue. Speculative squeeze to analyst $3.50 target and beyond.

Bull — Pilot data is positive enough to secure partnership/distribution and non-dilutive funding, extended-wear patch advances, and arrhythmia product gains modest concierge traction. Losses narrow, dilution slows, and market re-rates micro-cap medtech on de-risking toward FDA filing.

Neutral — Breakthrough hype fades but IP and cash sustain company. ALIGN-ACS data is mixed — promising but requiring larger study. Company cuts burn, signs a small distribution deal, and treads water with flat revenue and periodic small raises, leaving stock range-bound around current levels.

Bear — Post-60% spike profit-taking and follow-on offering crush momentum. Early commercial sales disappoint as shareholder letter foreshadowed, heart-attack data is incremental not breakthrough, and FDA path extends. Continued $3M+ quarterly burn forces further dilution below $0.50, returning stock toward 52-week lows.

Hyper Bear — ALIGN-ACS fails to show MI accuracy, FDA rejects or demands large pivotal trial company cannot fund, key partner ClearCardio churns, cash runs out, and BEAT does a toxic raise/reverse split. Nasdaq delisting risk emerges and equity is effectively wiped out despite patents.

03 · Fundamentals

Key Financial Metrics

Earnings Per Share (EPS): N/A (negative)
Revenue: N/A (~$0M pre-commercial)
P/E Ratio: N/A (unprofitable)
P/S Ratio: N/A (pre-revenue)
Market Cap: $36.86M
Net Income: ~-$5.0M (Q2 2026 quarterly)
Dividend Yield: 0.00%
52-Week Low: $0.35
52-Week High: $4.00

02 · Scenario Modeling

Technical Overview

Quant overlays derived from the existing 1Y OHLCV series: trend stack, sigma bands, regression fit, drawdown regime, and a composite signal model.

RSI (14)

75.7

Momentum Stack

1M +55.7% / 3M -0.7%

Volatility Regime

162.8% 20D vol

Regression Fit

+116.3% vs trend

Close20D MA50D MA200D MABollinger (20, 2σ)Regression channel centerline

Drawdown Curve

Distance from rolling peak, useful for regime stress and recovery speed.

-81.0%

Trend Regime

neutral

Mixed stack

Composite Signal

bearish

Bearish (-3)

Mean Reversion

bullish

+3.98 sigma

Breakout Status

bullish

Above 20D high

Range Percentile

bearish

8th pct

Volume Impulse

bullish

19.54x 20D avg

Quant Dashboard

A compact read on trend persistence, stretch, realized risk, and breakout behavior.

1M Return: +55.7%
6M Return: -45.5%
1Y Return: N/A
ATR (14): $0.07
20D Vol: 162.8%
60D Vol: 118.4%
Regression R²: 0.60
Price Z-Score: +3.98
52W High: $4.00
52W Low: $0.35
Range Position: 8th pct
Latest Volume: 404.2M

04 · Research

Micro Analysis

Pre-revenue micro-cap with validated core tech but failed early commercial execution, high cash burn, and dependence on future FDA clearance and partnerships.

Pre-commercial financial profile

Q2 2026 net loss $5.0M ($4.1M ex-transition costs), operating cash outflow $3.3M. No meaningful revenue disclosed; commercial launch described as 'initial' with multiple signed agreements in concierge practices. With ~56M shares implied ($36.86M / $0.6542), quarterly burn implies <12 months runway without further dilution despite lowered 2026 outflow guidance.

Commercialization admission

Sept 21, 2026 letter from Chairman Ferrari and Founder Vajdic states 'most important lesson is that scaling commercialization ourselves' is problematic (truncated disclosure implies pivot to partners). First partners ClearCardio and Atelier Health plus flagship sites in NY, Dallas, South Florida, SoCal are tiny concierge footprint. Company-touted $250-$500M concierge TAM is unvalidated and self-estimated.

Regulatory reality vs Breakthrough hype

Breakthrough Device Designation for HeartBeam System for at-home heart-attack assessment is NOT clearance/approval — it only offers expedited interaction. Cleared products cover arrhythmia and 12-lead synthesis only. Heart-attack detection requires ALIGN-ACS and Indonesian HEADSTART-ACS pilot data (full ALIGN results pending TCT 2026) plus future FDA submission, adding 12-24+ months of clinical/regulatory risk.

Serial dilution and financing overhang

Strengthened balance sheet via $11.5M public offering (with over-allotment) in Q1 2026 and $10M offering of 12.5M shares (~$0.80/share) closed recently, led by customer ClearCardio plus insiders. Pattern shows inability to fund via operations; further raises highly likely, capping any spike and permanently impairing per-share value for a $36M market cap issuer.

Tiny organization and execution risk

16 employees to develop hardware, AI-ECG algorithms with Mount Sinai, run two heart-attack pilot studies, pursue FDA filings, build extended-wear patch prototype for $2B ambulatory market, and launch commercially across four geographies. Bandwidth and commercial execution risk is extreme versus large competitors (iRhythm, Philips, GE, Medtronic) in $133B cardiac diagnostics market.

04 · Research

Macro Analysis

Cardiac diagnostics TAM is large and growing, but reimbursement, competition, and small-cap medtech funding conditions favor incumbents and well-capitalized disruptors.

Large but crowded cardiac diagnostics market

PatentVest cites $133B cardiac diagnostics market and company targets $2B ambulatory monitoring patch market. Tailwind from aging population, decentralization, and AI-ECG adoption. However incumbents and well-funded players (iRhythm, Abbott, Philips, GE Healthcare) dominate channels, payer contracts, and R&D spend.

Reimbursement and adoption barrier

Ambulatory ECG requires CPT codes, payer coverage, and health-system workflow integration. Concierge cash-pay avoids reimbursement short-term but limits scale. At-home heart-attack assessment faces highest evidentiary and liability bar — payers and ER physicians will demand large outcome studies beyond pilots.

Small-cap medtech funding environment

Higher-for-longer rates and risk-off for pre-revenue medtech in 2025-2026 force dilutive equity raises at depressed prices. BEAT's sub-$1 penny-stock status risks Nasdaq compliance pressure, wider spreads, and institutional avoidance, raising cost of capital versus profitable surgical equipment peers like Intuitive Surgical and Teleflex highlighted in Q2 2026 roundups.

Speculative micro-cap trading dynamics

404M volume day (~7x float), 59.5% spike, prior mentions in short-squeeze lists, 52-week range $0.35-$4.00 (-83.6% from high). Pattern indicates retail momentum and short-covering, not fundamental accumulation. Such moves historically fully retrace within weeks for pre-revenue biotech without revenue follow-through.

05 · Growth

Untapped Revenue Opportunities

Concierge / direct-pay arrhythmia monitoring

low

FDA-cleared HeartBeam System for arrhythmia assessment sold to concierge practices (ClearCardio, Atelier Health) as cash-pay cardiac insight tool. Low regulatory friction, early flagship sites provide reference accounts if retention and repeat ordering materialize.

At-home heart-attack detection (ALIGN-ACS / HEADSTART-ACS)

high

Breakthrough-designated indication to assess possible heart attack at home using 3D VECG + 12-lead synthesis + Mount Sinai AI. If validated and cleared, unlocks ER triage, remote monitoring, and Indonesian government-supported deployment. Largest value driver but pre-clinical proof.

12-lead extended-wear patch for ambulatory monitoring

medium

Working prototype completed targeting $2B ambulatory cardiac monitoring market dominated by Zio/iRhythm. Cable-free 12-lead patch would be differentiated vs single-lead patches if battery, wearability, and AI accuracy prove out and partnership enables manufacturing/scale.

06 · Catalysts

Headwinds & Tailwinds

↓ Headwinds

No meaningful revenue with ongoing burn and dilution

high

Heart-attack claim unproven and distant

high

Core bull thesis depends on pilot data (TCT 2026) translating to FDA clearance, reimbursement, and clinical adoption. Sensitivity/specificity for MI from ambulatory 3-lead synthesis is technically hard; failure or delay strands valuation.

Go-to-market failure and scale disadvantage

high

Management admits direct scaling is not working with only 16 staff. Without a strategic distributor or acquirer, concierge rollout cannot drive material revenue. Competing against entrenched ECG/Holter players with salesforces, payer contracts, and hospital IT integration.

Post-spike technical exhaustion and penny-stock risk

medium

RSI 75.7 overbought, close $0.6542 well below $0.95 high and $0.74 VWAP on record 404M volume. Prior -83.6% drawdown from $4.00 shows chronic downtrend. High volatility, potential Nasdaq bid-price compliance issues, and pump-and-dump dynamics risk sharp retracement.

↑ Tailwinds

FDA Breakthrough Designation + existing clearances

medium

Two FDA clearances de-risk base platform; Breakthrough Designation for heart-attack assessment provides FDA engagement, prioritized review potential, and marketing credibility for partnerships and pilot recruitment.

Mount Sinai AI collaboration

medium

Strategic collaboration to develop next-gen AI-ECG algorithms starting with heart-attack detection adds clinical validation, data access, and KOL endorsement critical for future FDA submission and payer acceptance.

Differentiated IP portfolio

medium

26 issued patents worldwide, first cable-free 12-lead synthesis claim, plus new acoustic sensing/thoracic impedance patent enabling digital stethoscope and heart-failure monitoring optionality. Creates acquisition option value for larger cardiac players.

07 · TL;DR

Analysis Summary

Ticker: BEAT
Company: Heartbeam, Inc. Common Stock
Analysis Date: 2026-10-06
Price at Analysis: $0.65
Rating: Sell
1Y Price Target: $0.35
3Y Price Target: $0.45
Market Cap: $36.86M
P/E Ratio: N/A (unprofitable)

This analysis was generated on 2026-10-06 when BEAT was trading at $0.65. The base-case 1-year price target is $0.35 (-46.5% implied return). Scenario range: $0.10 (hyper bear) to $3.50 (hyper bull).

Disclaimer: This report is generated by an AI model and is for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Past performance is not indicative of future results. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Executive Summary

Scenario Analysis

Scenario	1Y Target	1Y Growth	3Y Target	3Y Growth
↑↑Hyper Bull	$3.50	+438.5%	$7.00	+976.9%
↑Bull	$1.50	+130.8%	$3.00	+361.5%
→Neutral	$0.65	+0.0%	$0.90	+38.5%
↓Bear	$0.35	-46.2%	$0.45	-30.8%
↓↓Hyper Bear	$0.10	-84.6%	$0.05	-92.3%

↑↑Hyper Bull

1Y$4

3Y$7

1Y %+438.5%

3Y %+976.9%

↑Bull

1Y$2

3Y$3

1Y %+130.8%

3Y %+361.5%

→Neutral

1Y$1

3Y$1

1Y %+0.0%

3Y %+38.5%

↓Bear

1Y$0

3Y$0

1Y %-46.2%

3Y %-30.8%

↓↓Hyper Bear

1Y$0

3Y$0

1Y %-84.6%

3Y %-92.3%

Micro Analysis

Pre-revenue micro-cap with validated core tech but failed early commercial execution, high cash burn, and dependence on future FDA clearance and partnerships.

Pre-commercial financial profile

Commercialization admission

Regulatory reality vs Breakthrough hype

Serial dilution and financing overhang

Tiny organization and execution risk

Macro Analysis

Cardiac diagnostics TAM is large and growing, but reimbursement, competition, and small-cap medtech funding conditions favor incumbents and well-capitalized disruptors.

Large but crowded cardiac diagnostics market

Reimbursement and adoption barrier

Small-cap medtech funding environment

Speculative micro-cap trading dynamics

Untapped Revenue Opportunities

Concierge / direct-pay arrhythmia monitoring

low

At-home heart-attack detection (ALIGN-ACS / HEADSTART-ACS)

high

12-lead extended-wear patch for ambulatory monitoring

medium

Headwinds & Tailwinds

↓ Headwinds

No meaningful revenue with ongoing burn and dilution

high

Heart-attack claim unproven and distant

high

Go-to-market failure and scale disadvantage

high

Post-spike technical exhaustion and penny-stock risk

medium

↑ Tailwinds

FDA Breakthrough Designation + existing clearances

medium

Mount Sinai AI collaboration

medium

Differentiated IP portfolio

medium

Analysis Summary

Ticker: BEAT
Company: Heartbeam, Inc. Common Stock
Analysis Date: 2026-10-06
Price at Analysis: $0.65
Rating: Sell
1Y Price Target: $0.35
3Y Price Target: $0.45
Market Cap: $36.86M
P/E Ratio: N/A (unprofitable)

This analysis was generated on 2026-10-06 when BEAT was trading at $0.65. The base-case 1-year price target is $0.35 (-46.5% implied return). Scenario range: $0.10 (hyper bear) to $3.50 (hyper bull).